Pentosan polysulfate sodium (PPS) is a semi-synthetic sulfated polysaccharide derived from beechwood hemicellulose — a glycosaminoglycan, not a peptide. It is FDA-approved as Elmiron for the bladder pain of interstitial cystitis and is used off-label, and in veterinary orthopedics, for joint and cartilage support. Its most important modern safety finding is pigmentary maculopathy, a distinctive and potentially irreversible retinal toxicity identified in 2018 that led to an FDA label change in 2020.
Category: Anti-Aging / Regenerative. Evidence rating: B (meaningful human data).
Clinical status: FDA-approved (Elmiron) for interstitial cystitis bladder pain. Joint and cartilage use is off-label in humans and established in veterinary medicine.
PPS is a heparin-like sulfated polysaccharide. In the bladder it is thought to adhere to and supplement the deficient glycosaminoglycan mucosal layer, restoring a barrier against irritants in urine — the rationale for its interstitial cystitis indication. In connective tissue it inhibits…
Safety considerations: Pigmentary maculopathy is the defining long-term risk — dose- and duration-dependent retinal pigment epithelium changes that can impair vision and may progress even after stopping. Baseline and periodic retinal examination is required for any extended use; Anticoagulant and antiplatelet effect from its heparin-like structure — raises bleeding risk, particularly around surgery or with other anticoagulants; Gastrointestinal effects (nausea, diarrhea, abdominal pain) are common with oral dosing.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~4000-6000 Da (polydisperse polysaccharide) |
|---|---|
| CAS number | 37300-21-3 |
| Half-life | ~24-27 hours (oral) |
| Bioavailability | ~3% oral |
| Production method | semi-synthetic |
| Anti-doping status | not-listed |
| US regulatory status | FDA-approved prescription drug (Elmiron) for interstitial cystitis. 2020 label change added the pigmentary maculopathy warning. Joint use is off-label. |
Related peptides: GDF-11.
No. It is a semi-synthetic sulfated polysaccharide (a glycosaminoglycan) derived from beechwood hemicellulose. It appears in this library because it is commonly discussed and stacked alongside BPC-157 and TB-500 in joint and regenerative protocols.
Chronic PPS use is associated with a distinctive retinal pigment epithelium disorder, first described in 2018 and added to the FDA label in 2020. Risk rises with cumulative dose and duration, changes can be permanent, and they may progress even after stopping. Anyone on extended PPS should have baseline and periodic retinal imaging.
Oral bioavailability is only around 3%. Veterinary orthopedic use is largely parenteral for that reason. Human injectable use is off-label and not supported by an approved human formulation.
It is frequently presented that way in joint protocols. The important caution is not peptide interaction but PPS's anticoagulant activity and the retinal risk — neither of which the peptides mitigate, and both of which require monitoring the peptides do not.